 Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntingtons Disease HD trial suggesting a cognitive benefit in patients with mildly advanced disease Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntingtons Disease HD trial suggesting a cognitive benefit in patients with mildly advanced disease 